Non-Melanoma Skin Cancers Coverage from Every Angle
Advertisement
Advertisement

Alexander C. J. van Akkooi, MD, PhD, on Domatinostat Plus Avelumab for Merkel Cell Carcinoma

Posted: Friday, June 18, 2021

Alexander van Akkooi, MD, PhD, of The Netherlands Cancer Institute, discusses the ongoing phase II MERKLIN 2 study, being conducted across Europe and the United States, to investigate the efficacy and safety of the HDAC inhibitor domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel cell carcinoma progressing on anti–PD-L1 antibody therapy.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.